GLP 1 fill finish capacity stays in demand for 2027 says a CDMO hiring outlook
A recruiting firm forecast says GLP 1 drugs will still drive most new sterile filling demand at contract plants in 2027, with fill line and peptide quality staff hardest to hire. It gives no supply figures, and no maker has announced limits.
Who feels it
-
Sellers
Adjust
Contract plants are urged to invest in GLP 1 filling while sterile and peptide quality staff stay scarce.
-
Patients
Worth knowing
No supply change now; a squeeze on pen filling would show first as patchy stock of some strengths.
-
Pharmacies
Worth knowing
Watch the FDA shortage list and maker notices for any pen strength going short.
-
Prescribers
Passes by
—
-
Payers
Passes by
—
GLP 1 fill finish capacity will stay in heavy demand through 2027, according to a contract manufacturing outlook from the recruiting firm Vector Talent, reported by Pharma Manufacturing on November 16. The firm says GLP 1 drugs still account for most new demand for the sterile lines that put medicine into pens and syringes. It also expects skilled staff for those lines, and for peptide quality control, to be among the hardest people to hire next year. The forecast gives no supply figures for any GLP 1 product.
What the Vector Talent outlook says
Vector Talent, a staffing and recruiting firm for the drug industry, publishes a yearly outlook for contract development and manufacturing organizations, the outside plants that many drug makers pay to produce and package medicines. Its CDMO Outlook for 2027 says two kinds of medicine pulled ahead in 2026, GLP 1 drugs and oligonucleotides, while cell and gene therapy struggled. Its prediction for next year is that GLP 1 drugs will still drive most new demand for fill and finish work, the last sterile step in which a drug is filled into a pen, cartridge or syringe and sealed. The firm's advice to contract plants is blunt: commit now to oligonucleotides and GLP 1 filling, and keep smaller bets on cell and gene therapy.
The report treats people, not machines, as the main limit. According to Pharma Manufacturing, Vector names sterile fill finish, peptide quality control and oligonucleotide chemistry and controls as the roles that will be hardest to fill in 2027. Candidates for fill finish jobs point to device quality assurance and validation under the European Annex 1 rules for sterile production as the sharpest skill gaps. The outlook is behind a sign up form on the firm's website, and its public preview does not mention GLP 1 drugs, so the claims here are as the trade journal reported them. Vector earns its money placing staff at these companies, which gives it a reason to stress hiring shortages.
Why GLP 1 fill finish capacity matters for patients
For people on these drugs, the fill line is where shortages have tended to bite. GLP 1 medicines for diabetes and weight loss are mostly given by injection from prefilled pens, and each pen has to be filled and assembled under sterile rules. When demand outran supply in recent years, the FDA listed semaglutide and tirzepatide as in shortage, and that status opened the door to large scale compounding of copies. The FDA declared those shortages over in late 2024 and early 2025, and the grace periods for mass compounding ended soon after. Any new squeeze on GLP 1 fill finish capacity would therefore matter twice: first through missed refills, then through renewed pressure on the rules that govern compounded versions.
When demand outran supply in recent years, the FDA listed semaglutide and tirzepatide as in shortage, and that status opened the door to large scale compounding of copies.
Drug makers have been buying and building their own lines to cut that risk. When Novo Holdings closed its purchase of the contract maker Catalent in December 2024, it said three Catalent fill finish sites, in Anagni in Italy, Bloomington in Indiana and Brussels in Belgium, would be sold on to Novo Nordisk. Lilly has also announced new US plants as demand outran its own capacity, as we reported when it planned four more US plants. The table below sets out the points in the Vector outlook alongside the context we could check. It shows a sector where most new filling demand still comes from the same few drugs, and where staff are the limit.
| Item | What was reported | Source |
|---|---|---|
| Main driver of new fill finish demand in 2027 | GLP 1 drugs | Vector Talent via Pharma Manufacturing |
| Hardest roles to fill in 2027 | Sterile fill finish, peptide quality control, oligonucleotide chemistry and controls | Vector Talent via Pharma Manufacturing |
| Prefilled syringe market | $9.4 billion in 2026, forecast $20.3 billion by 2035 | Pharma Manufacturing |
| Catalent fill finish sites moved to Novo Nordisk | Anagni, Bloomington, Brussels | Novo Holdings, December 2024 |
| Lilly RNAi metabolic disease deal with SanegeneBio | Up to $1.2 billion in milestones | Pharmaceutical Technology, November 2025 |
Oligonucleotides compete for the same plants
The second half of the outlook is about oligonucleotides, short strands of genetic material used as drugs. Vector says capacity for them will sell out before it is built in 2027, and it quotes an unnamed supplier saying 70 percent of a new production train is booked six months before it opens. These drugs are moving from rare diseases into common conditions, including heart disease, liver disease and obesity. The report points to Lilly's RNAi deal with SanegeneBio for metabolic disease, worth up to $1.2 billion in milestone payments, as a sign of interest in obesity. For GLP 1 supply, the overlap is mainly in sterile filling and quality staff, since both kinds of medicine need the same scarce people to release product.
A manager at the oligonucleotide supplier Hongene Biotech told Pharma Manufacturing that contract plants let drug developers move faster without building their own sites. That view comes from a company that sells this service, and the article gave no data on how much capacity exists or how much is booked. For a reader trying to judge the risk of another GLP 1 shortage, the useful signal is narrower. Contract plants are being told to keep investing in GLP 1 filling, and staff for sterile lines are scarce. Neither point shows a shortage is coming, and none of the companies that make or fill GLP 1 pens has announced new limits.
What to watch on GLP 1 supply in 2027
Three markers will show whether the forecast matters for patients. The first is the FDA drug shortage list, which shows when a product is in short supply and which strengths are affected. The second is new plant openings and fill line approvals from the major makers and their contract partners, which add pens to the market. The third is the switch to oral GLP 1 tablets, which need no sterile filling at all and could ease pressure on pen lines if more patients move to them. Each of these is public and can be checked, unlike a recruiter's forecast based on conversations with clients. We follow all three on our supply beat.
Prices are the other side of the same question. Novo Nordisk cuts the US list price of Wegovy and Ozempic on January 1, cash prices keep falling and coverage rules are shifting, which could raise demand further. If demand grows faster than filling capacity, the first signs would be patchy stock of certain strengths at pharmacies rather than a formal shortage. Readers can check the forecast in the Pharma Manufacturing article. The Catalent site sale is described in the Novo Holdings announcement. Neither document gives a date or a figure for future GLP 1 supply, and readers should treat the outlook as an industry view.
Conclusion
The Vector outlook says GLP 1 fill finish capacity will stay in demand in 2027 and that skilled staff, not equipment, are the tightest limit. It comes from a recruiter with an interest in hiring stories and gives no supply figures for any GLP 1 drug. For patients, nothing has changed yet. The FDA shortage list and new fill lines remain the signals to watch. This is industry reporting, not medical advice.
Source Vector Talent CDMO Outlook for 2027, as reported by Pharma Manufacturing (November 16, 2026); Novo Holdings release on Catalent (December 18, 2024)
Sources
- Pharma Manufacturing: Oligonucleotides, GLP-1s will continue to drive CDMO market in 2027, report (November 16, 2026)
- Novo Holdings: Novo Holdings completes acquisition of Catalent (December 18, 2024)
- Pharmaceutical Technology: SanegeneBio and Lilly RNAi licensing deal (November 10, 2025)
- Vector Talent: CDMO Outlook 2027 (preview page)
Spotted an error? Tell us through the contact form; we follow the corrections policy.